Kymera Therapeutics, Inc. - Laporan Laba Rugi (TTM)

Kymera Therapeutics, Inc.
US ˙ NasdaqGM ˙ US5015751044

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Kymera Therapeutics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 23 34 49 65 70 73 64 57 46 47 47 52 47 79 79 89 88 47 59 45
Change (%) 47.45 44.88 30.89 8.99 3.54 -12.47 -10.99 -19.01 1.88 -0.33 10.71 -9.33 67.77 1.04 11.51 -1.11 -46.24 25.10 -24.07
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 53 62 76 97 120 137 147 153 159 164 171 175 179 189 196 209 221 240 272 291
Change (%) 17.63 22.29 28.18 23.14 14.30 7.29 4.13 3.64 3.53 3.83 2.62 2.42 5.49 3.49 6.87 5.88 8.51 13.08 7.06
% of Revenue 228.75 182.48 154.03 150.84 170.42 188.13 230.58 269.75 345.16 350.76 365.40 338.70 382.62 240.59 246.40 236.15 252.85 510.38 461.38 650.56
Gross Operating Profit -30 -28 -27 -33 -50 -64 -83 -96 -113 -117 -124 -123 -132 -110 -116 -121 -134 -193 -213 -246
Change (%) -5.54 -5.09 23.15 50.98 29.57 29.70 15.71 16.98 4.21 5.48 -0.42 7.35 -16.55 5.22 3.70 11.02 44.34 10.16 15.68
% of Revenue -128.75 -82.48 -54.03 -50.84 -70.42 -88.13 -130.58 -169.75 -245.16 -250.76 -265.40 -238.70 -282.62 -140.59 -146.40 -136.15 -152.85 -410.38 -361.38 -550.56
SG&A 16 18 22 26 30 36 41 44 44 44 46 49 52 55 57 60 61 64 65 66
Change (%) 16.97 18.37 20.24 14.75 22.04 12.94 7.31 -0.25 -0.24 4.46 6.77 7.29 4.94 3.29 5.71 2.22 3.43 2.99 0.42
% of Revenue 67.53 53.57 43.77 40.21 42.34 49.90 64.39 77.62 95.60 93.61 98.11 94.61 111.96 70.03 71.59 67.86 70.15 134.97 111.12 146.95
R&D
Change (%)
% of Revenue
OpEx 68 80 98 123 150 173 188 197 203 208 216 224 232 244 253 269 283 304 337 357
Change (%) 17.48 21.40 26.42 21.38 15.84 8.47 4.83 2.77 2.71 3.96 3.50 3.49 5.36 3.44 6.60 5.06 7.41 10.97 5.77
% of Revenue 296.28 236.05 197.81 191.05 212.76 238.03 294.96 347.37 440.76 444.37 463.51 433.32 494.59 310.62 317.99 304.01 323.00 645.36 572.50 797.51
Operating Income -45 -46 -48 -59 -79 -101 -124 -140 -157 -161 -170 -172 -185 -166 -173 -181 -195 -257 -278 -312
Change (%) 2.21 4.15 21.85 34.98 26.74 23.64 12.94 11.57 2.96 5.20 1.52 7.33 -10.45 4.58 4.36 8.09 31.47 8.38 12.09
% of Revenue -196.28 -136.05 -97.81 -91.05 -112.76 -138.03 -194.96 -247.37 -340.76 -344.37 -363.51 -333.32 -394.59 -210.62 -217.99 -204.01 -223.00 -545.36 -472.50 -697.51
Interest Expense -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0
Change (%) -2.54 -8.70 -11.43 62.37 15.89 12.57 13.71 -25.00 4.76 3.41 2.20 9.14 -3.45 -1.53 -1.55 27.37 2.89 11.24 13.00
% of Revenue -0.51 -0.34 -0.21 -0.14 -0.21 -0.24 -0.31 -0.39 -0.37 -0.38 -0.39 -0.36 -0.43 -0.25 -0.24 -0.21 -0.28 -0.53 -0.47 -0.70
Net Income -44 -46 -48 -58 -79 -100 -124 -139 -154 -155 -159 -158 -167 -147 -155 -158 -167 -224 -241 -275
Change (%) 2.64 4.70 22.35 35.26 26.85 23.56 12.60 10.34 0.63 2.74 -0.92 6.26 -12.24 5.19 2.11 6.09 33.67 7.60 14.34
% of Revenue -192.45 -133.96 -96.81 -90.50 -112.31 -137.60 -194.23 -245.69 -334.72 -330.60 -340.80 -305.01 -357.47 -186.99 -194.67 -178.27 -191.26 -475.57 -409.07 -616.03

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista